1. Medtech Insight
  2. >>Archive

Filling in the Gaps in AAA Repair

The first stent grafts created a market for the endovascular repair of abdominal aortic aneurysms. They also created new problems for start-ups to overcome. New companies have risen to the problem of avoiding endoleaks, with new stent graft designs and attachment systems, and also solutions for continuous monitoring.

We'll know that the technology for the endovascular repair of abdominal aortic aneurysms (AAAs) has finally arrived when clinicians start talking about treating the disease at early stages, to head off potential deleterious consequences--chiefly death --from unanticipated rupture. But today, because of the shortcomings of all treatment options, both surgical and endovascular, the tendency is to put off treatment until absolutely necessary; the watchword is, "watchful waiting."

An AAA is a weakened section of the largest artery of the body; blood pressure can make it progressively balloon out until it finally ruptures, in which case patients can bleed to death within minutes. Today, aneurysms aren't generally repaired until their risk of rupture outweighs the risks of treatments, and physicians, mostly vascular surgeons, face a complex decision-making process in determining when and how to treat patients with AAAs. Younger, healthier patients tend to go to surgery, since the long-term durability of implanted devices hasn't yet been demonstrated. Certain older patients get endovascular procedures, provided that they don't suffer from the many exclusions that come with the relatively new devices

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.